Lateral Flow Diagnostics Contract Development and Manufacturing
Abingdon Health plc (LSE:ABDX) has successfully transformed its operational Business model from pandemic-related testing into an internationally recognised contract development and Manufacturing organisation (CDMO) specializing in rapid lateral flow diagnostic tests. Listed on AIM and a constituent of the FTSE AIM All-Share index, the York-headquartered company provides end-to-end technical services—from assay design and clinical validation through to high-volume automated manufacturing, regulatory compliance, and commercial distribution.
Diverse CDMO Customer Pipelines Across Human and Animal Health
The engine of Abingdon Health's commercial turnaround is its rapidly expanding CDMO customer base. Operating state-of-the-art automated manufacturing facilities in York and Doncaster, the company develops and manufactures lateral flow test strips for global corporate clients across infectious diseases, oncology, fertility, animal health, and environmental water testing. By securing multi-year contract manufacturing agreements, Abingdon establishes dependable recurring revenues and maximizes automated factory throughput.
Consumer Commercialisation: Salistick Saliva Pregnancy Test
Complementing its contract manufacturing services, Abingdon Health (LSE:ABDX) drives direct commercial revenues through proprietary and partnered consumer diagnostic products. A notable commercial asset is Salistick®, the world's first saliva-based rapid pregnancy test. The company has secured retail pharmacy distribution for Salistick across major UK pharmacy chains, supermarkets, and international retail markets, providing consumers with a convenient, non-invasive alternative to traditional urine-based testing.
Financial Performance, Revenue Growth, and Breakeven Trajectory
In its published statutory accounts and periodic operational updates, Abingdon Health (LSE:ABDX) reported substantial revenue growth driven by expanding CDMO service billings and rising commercial product sales. Gross margins have expanded as automated production lines achieved economies of scale, while operating cash outflow has narrowed significantly. The company does not currently pay a dividend, prioritizing Capital conservation and Working Capital optimization to achieve sustained operational Cash Flow breakeven.
Quality Compliance Dynamics and Forthcoming Milestones
Abingdon Health (LSE:ABDX) operates in an internationally regulated diagnostic manufacturing environment requiring strict adherence to ISO 13485 standards and UK/EU in-vitro diagnostic medical device regulations (IVDR). Key catalysts over the next twelve months include announcing new commercial contract manufacturing agreements with multinational healthcare clients, expanding Salistick distribution into overseas retail territories, and publishing audited full-year financial accounts demonstrating continued revenue expansion.
Sector Context and Market Backdrop
Lateral flow tests became widely familiar through Pandemic testing, but the technology has a much broader role in healthcare. Rapid tests are used in fertility and pregnancy testing, infectious disease screening, food safety, animal health and many other fields. Contract development and manufacturing organisations support diagnostic brands by turning an assay concept into a validated, regulated product that can be produced at scale, including the technical documentation required for market access in different regions.
What to Watch Next
Items to follow include the breadth of the CDMO customer base, the development of consumer products such as the Salistick saliva pregnancy test and the progress of manufacturing automation. Regulatory technical file support is a valuable service for clients entering new markets, so announcements of new contracts or regulatory clearances help to show how the model is progressing. Updates on margins and Operating Cash Flow will indicate how production efficiency is developing alongside revenue.





_11_16_2026_07_31_57_000112.jpg)
Please wait processing your request...